Diphtheria is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Diphtheria have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Diphtheria compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Diphtheria overview
Diphtheria is a bacterial infection caused by Corynebacterium diphtheriae, primarily affecting the respiratory tract but potentially impacting other mucous membranes. It spreads through respiratory droplets and contact with contaminated surfaces. The hallmark symptom is the formation of a thick grayish membrane in the throat, accompanied by fever, sore throat, and difficulty breathing. Complications can include airway obstruction, myocarditis, and neurological issues. Before widespread vaccination, diphtheria was a significant cause of morbidity and mortality, particularly in children. Prevention is primarily through vaccination, typically administered in childhood as part of routine immunization schedules. Prompt diagnosis and treatment with antibiotics and antitoxins are crucial to mitigate the severity and spread of the disease.
For a complete picture of PTSR and LoA scores for drugs in Diphtheria, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
